LETTERS TO THE EDITOR 877829C PHXXX10.1177/1715163519877829C P J / R P CC P J / R P C
research-article2019
Pharmacists and hypertension I was reading with great interest the peer-reviewed, published research article in the July/August CPJ titled "Pharmacist prescribing and care improves cardiovascular risk, but is it cost-effective? A cost-effectiveness analysis of the R x EACH study. " 1 The results are fantastic! Pharmacists can play such an important role in health care by screening patients for hypertension and cardiovascular risk. This research shows that if pharmacists would just take care of the patient on the other side of the counter, they could positively affect outcomes, satisfy our own financial requirements and save payers' money at the same time. ■
-Bruce Winston President, Sandstone Pharmacies
Calgary, Alberta Reference (6):411-7], the following corrections need to be noted to reflect changes to the Canadian product monograph for the Japanese encephalitis vaccine effective March 2018:
• Table 1 : Japanese encephalitis vaccine use in adults following a rapid schedule of 0 and 7 days is not an off-label use but rather an approved regimen for adults aged 18-65 years • Table 1 : Japanese encephalitis vaccine use in children aged 2 months to 17 years is not an off-label use but rather an approved indication • Page 414: Under Japanese encephalitis vaccine, sentences 3-5 of the third paragraph should instead read: "Recently, JEV-VC has been approved for use in Canada in children ≥2 months of age (half a dose recommended for children aged ≥2 months to <3 years) on days 0, 28. 33, 36 The vaccine should be considered for pediatric travellers to endemic areas, as disease severity is high in this population. " 32,36 • Page 414: Under Japanese encephalitis vaccine, the second sentence of the fourth paragraph should instead read: "Recently, a rapid dosing schedule for adults aged 18 to 65 years has been approved for use in Canada, with a dose on day 0 and day 7 completed at least 1 week before risk of exposure, with seroconversion comparable to the 0-and 28-day schedule. " 32, 37 Readers should also note in Table 1 that the duration of protection conferred by the oral cholera/ETEC-diarrhea vaccine should read 3 months to 2 years. ■
